Future Search Trials of Dallas
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ashmore, Erin
NCT05217927 / 2021-005239-22: Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

Completed
4
698
Europe, Canada, US
Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing, Placebo comparator dosing
Pfizer, Biohaven Pharmaceuticals Holding Company Limited, Pfizer Inc.
Migraine
10/24
12/24
NCT04693351 / 2020-004653-69: Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

Active, not recruiting
3
700
Europe, Canada, US, RoW
Troriluzole, Placebo
Biohaven Pharmaceuticals, Inc.
Obsessive-Compulsive Disorder
04/25
04/25
NCT04649242 / 2020-003517-35: Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Recruiting
3
2100
Europe, Canada, Japan, US, RoW
Rimegepant/BHV3000, Matching placebo
Pfizer
Pediatric Migraine
01/29
01/29
REPOSA, NCT06146101: RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

Active, not recruiting
2/3
560
US
IHL-42X Low Dose, Phase 2 Investigational Product - IHL-42X Low dose, IHL-42X High Dose, Phase 2 Investigational Product - IHL-42X High dose, Placebo, Phase 2 Placebo, IHL-42X (Optimal Dose), Phase 3 Investigational Product - IHL-42X, Dronabinol, Phase 3 Comparator - Reference Listed Drug/Dronabinol, Acetazolamide, Phase 3 Comparator - Reference Listed Drug/Acetazolamide, Phase 3 Placebo
Incannex Healthcare Ltd
Obstructive Sleep Apnea
12/26
12/26
NCT04804033: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Terminated
2/3
1753
US
BHV-3500 (zavegepant), Placebo
Pfizer
Migraine
03/24
03/24
NCT06419608: Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

Recruiting
2
300
US
BHV-7000, Placebo
Biohaven Therapeutics Ltd.
Major Depressive Disorder
05/25
07/25
Yoon, Suzie
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ashmore, Erin
NCT05217927 / 2021-005239-22: Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

Completed
4
698
Europe, Canada, US
Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing, Placebo comparator dosing
Pfizer, Biohaven Pharmaceuticals Holding Company Limited, Pfizer Inc.
Migraine
10/24
12/24
NCT04693351 / 2020-004653-69: Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

Active, not recruiting
3
700
Europe, Canada, US, RoW
Troriluzole, Placebo
Biohaven Pharmaceuticals, Inc.
Obsessive-Compulsive Disorder
04/25
04/25
NCT04649242 / 2020-003517-35: Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Recruiting
3
2100
Europe, Canada, Japan, US, RoW
Rimegepant/BHV3000, Matching placebo
Pfizer
Pediatric Migraine
01/29
01/29
REPOSA, NCT06146101: RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

Active, not recruiting
2/3
560
US
IHL-42X Low Dose, Phase 2 Investigational Product - IHL-42X Low dose, IHL-42X High Dose, Phase 2 Investigational Product - IHL-42X High dose, Placebo, Phase 2 Placebo, IHL-42X (Optimal Dose), Phase 3 Investigational Product - IHL-42X, Dronabinol, Phase 3 Comparator - Reference Listed Drug/Dronabinol, Acetazolamide, Phase 3 Comparator - Reference Listed Drug/Acetazolamide, Phase 3 Placebo
Incannex Healthcare Ltd
Obstructive Sleep Apnea
12/26
12/26
NCT04804033: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Terminated
2/3
1753
US
BHV-3500 (zavegepant), Placebo
Pfizer
Migraine
03/24
03/24
NCT06419608: Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

Recruiting
2
300
US
BHV-7000, Placebo
Biohaven Therapeutics Ltd.
Major Depressive Disorder
05/25
07/25
Yoon, Suzie
No trials found

Download Options